- Nasdaq falls flat, U.S. stocks battle to recover from tech sell-off to kick off 2026 (COMP:IND:) Seeking Alpha
- Jobs data may jolt stocks from holiday calm The Express Tribune
- S&P 500, Nasdaq see muted start to 2026 after last year’s robust gains Business Recorder
- MarketBeat Week in Review – 12/29 – 01/02 TradingView — Track All Markets
- Wall Street Rotated Out Of Tech As Valuation Worries Crept In Finimize
Category: 3. Business
-
Nasdaq falls flat, U.S. stocks battle to recover from tech sell-off to kick off 2026 (COMP:IND:) – Seeking Alpha
-

Distributed energy resource aggregations: Self-paced training available
ISO New England now offers self-paced training for distributed energy resources (DERs) interested in participating in the region’s wholesale electricity markets as part of an aggregation.
The training module provides an overview of market participation models established under Federal Energy Regulatory Commission Order (FERC) No. 2222. It also includes a detailed summary of potential system impacts. The estimated viewing time is approximately 20 minutes.
A downloadable PDF is also available and includes a printable version of the participation model descriptions covered in the self-paced training.
For additional information, visit the Order No. 2022 Key Project page.
ISO New England offers a variety of training materials to help participants understand the region’s wholesale electricity market and power system. Is there something specific you’d like to see? Take a short survey to provide your feedback.
Continue Reading
-

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. ,Jan. 02, 2026 (GLOBE NEWSWIRE) —Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that onJanuary 1, 2026 , it awarded inducement grants to two new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 22,800 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in
June 2024 . These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).About
Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.Intellia Contacts:
Investors:
Jason Fredette Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.comMedia:
Matt Crenson TenBridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com

Source: Intellia Therapeutics, Inc.
Continue Reading
-

ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company’s common shares to a new employee on January 2, 2026 (“Grant”).
The Grant was offered as material inducement to the employee’s employment. The Grant was approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipient to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.
The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing and outcome of the full LOTIS-7 trial, potential best-in-class results, future publication, compendia and regulatory strategy and the commercial opportunity; the success of the Company’s strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the strengthened balance sheet and expected cash runway into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company’s ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions and trade barriers and potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040SOURCE ADC Therapeutics SA
Continue Reading
-

U.S. builds on lead as top natural gas exporter
This winter, America’s natural gas keeps millions of Americans warm in their homes, powering everything from heating systems to holiday decorations. Beyond U.S. borders, the United States serves as a reliable, year-round supplier of liquefied natural gas (LNG), strengthening global energy security when demand rises, including during the winter months.
Already the world’s largest exporter of LNG, the United States is on track to double its LNG production capacity by 2029. America exports LNG — used for electricity generation, industrial production and to home heating — to 43 countries.
“We stand ready to provide any country with abundant, affordable energy supplies if you need them,” President Trump said of U.S. energy production at the U.N. General Assembly in September. “We’re proudly exporting energy all over the world.”
For each of the first nine months of 2025, U.S. LNG export volumes outpaced the same month in the prior year. In fact, in September, U.S. LNG exports topped 15 billion cubic feet per day (Bcf/d), a 25% increase over September 2024.
(State Dept./M. Gregory) U.S. producers are dramatically expanding their capacity to liquefy natural gas. Unlike piped natural gas, LNG can be shipped via tanker, dramatically expanding export opportunities. With new facilities coming online, U.S. exporters plan to double liquefaction capacity, adding an estimated 13.9 Bcf/d between 2025 and 2029, according to the U.S. Energy Information Administration.
Increased liquefaction capacity in the United States is driving an export surge for the entire region. Canada and Mexico plan to expand liquefaction capacity by 2.5 Bcf/d and 0.6 Bcf/d, respectively, over the next several years.
With the U.S. leading the way, the three nations’ increased capacity puts North America on pace to double LNG exports by 2029, the Energy Information Administration says.
Continue Reading
-
McCormick Completes Acquisition of Controlling Interest in McCormick de Mexico – McCormick
- McCormick Completes Acquisition of Controlling Interest in McCormick de Mexico McCormick
- McCormick acquires majority stake in Mexican joint venture for $750m By Investing.com Investing.com South Africa
- McCormick & Co Inc Completes Acquisition of Controlling Interest in McCormick de Mexico TradingView — Track All Markets
Continue Reading
-

NASA’s CSDA Program Announces Eight New Data Agreements
NASA’s Commercial Satellite Data Acquisition (CSDA) program announced eight new agreements with seven of its commercial partners, further advancing its mission to acquire data from commercial providers that support NASA’s Earth science research and applications and expand the quality, coverage, and range of Earth observation data NASA offers to the scientific community.
“These new agreements will provide users with a range of high-quality multispectral and SAR data that can be used in a variety of applications from environmental monitoring to surface deformation,” said CSDA Project Manager Dana Ostrenga. “In addition, they exemplify the CSDA program’s commitment to acquiring data that enhances and supports the agency’s application and research objectives.”
New Near-Global, Multispectral Imagery
In support of NASA programs and stakeholders, the CSDA program enacted three agreements with Planet, Airbus, and Vantor (formerly Maxar) to provide near‑global multispectral and pan‑sharpened electro‑optical satellite imagery of nearly all global land and coastal surfaces. This imagery has a spatial resolution of approximately 30 centimeters, 1 meter, and up to 10 meters (depending on the product) and is suitable for applications including environmental monitoring, agriculture, and urban applications. Data products will include top of atmosphere (TOA) radiances and surface reflectance across the visible and near‑infrared spectrum.
New SAR Data
In response to users’ need for synthetic aperture radar (SAR) data, and following rigorous technical and programmatic evaluation, CSDA executed five agreements for high‑resolution SAR imagery with Capella, ICEYE, MDA, Umbra, and Airbus. This SAR imagery includes tasked Spotlight, StripMap, Scan, Wide/Extended Spotlight, and Long‑Dwell modes, which provide all‑weather, day‑night imaging that complements the electro‑optical agreements and enhances NASA’s ability to monitor dynamic processes such as flooding, land deformation, sea‑ice motion, and infrastructure impacts. Further, under these agreements, each commercial partner will provide specific data requirements consistent with their respective instrument capabilities and performance, as well as tasking and archive access.
Increased Access and User Eligibility
The data acquired under these agreements will be made available to authorized commercial satellite data users in accordance with the CSDA program’s end user license agreements (EULAs). EULAs generally pertain to NASA‑funded investigators and designated collaborators and outline established mechanisms for accessing CSDA data, such as the CSDA Satellite Data Explorer (SDX) and related portals. Users can email the CSDA program to obtain additional information about user agreements, detailed product specifications, and procedures for requesting and accessing these commercial datasets for their research and application activities.
About the CSDA Program
NASA’s Earth Science Division (ESD) established the CSDA program to identify, evaluate, and acquire data from commercial providers that to support NASA’s Earth science research and applications. NASA recognizes the potential of commercial satellite constellations to advance Earth System Science and applications for societal benefit and believes commercially acquired data may also augment the Earth observations acquired by NASA, other U.S. government agencies, and NASA’s international partners.
All data from CSDA vendors are evaluated by the investigator-led CSDA project teams that assess the value of adding a vendor’s data to CSDA’s data holdings based on their quality and how they might benefit in the context of NASA Earth science research and applications.
Continue Reading
-

Michigan Gaming Control Board to meet January 13
DETROIT, Jan. 2, 2026 — The Michigan Gaming Control Board will meet in person at 10:00 a.m. on Tuesday, January 13, to conduct Board business regarding the implementation, administration, and enforcement of the provisions of the Michigan Gaming Control & Revenue Act, the Lawful Internet Gaming Act, and the Lawful Sports Betting Act as related to the licensing, regulation, and conduct of casino gaming, iGaming, and any other relevant matter in the State of Michigan.
The meeting is open to the public, and anyone can watch or listen to the meeting via Zoom or by telephone.
WHO: Michigan Gaming Control Board
WHAT: Regular Board Meeting
WHEN: 10:00 a.m., Tuesday, January 13, 2026WHERE:
- In Person: Cadillac Place, 3062 W. Grand Blvd., Ste. L-700, Detroit, MI 48202
- Online via Zoom: https://zoom.us/j/91518415571
- Phone: You may also join by calling 646-931-3860. The Webinar ID for the meeting is 915 1841 5571.
Please see the Board meeting notice for additional details, including information about requests for special accommodations. The notice includes instructions for remote participants who wish to address the Board in the public comment portion of the meeting. Anyone planning to participate in the public comment period is asked to register via email at MGCBweb@michigan.gov by 10:00 a.m. Tuesday, January 13, using a form on the agency’s website. Please provide your name and telephone number on the form.
The meeting agenda is available on the agency’s website.
Gambling in any form is for entertainment purposes only. If you or someone you know may have a gambling problem, call 1-800-GAMBLER or visit 800gambler.org. Help is available 24/7 and is free and confidential. Michigan citizens can also visit the Responsible Gaming page of the MGCB website for information on self-exclusion programs including the Disassociated Persons List and the Internet Gaming and Sports Betting Responsible Gaming Database, and DontRegretTheBet.org for additional tools to game responsibly.
The Michigan Gaming Control Board shall ensure the conduct of fair and honest gaming to protect the interests of the citizens of the state of Michigan. Learn more at Michigan.gov/MGCB.
Continue Reading
-

New York Ends Year With Fewest Fatalities Ever Recorded
Traffic Deaths Reach All-time Low: New York Ends Year With Fewest Fatalities Ever Recorded
Sharpest Declines in Outer Boroughs, Fatalities Down Across Travel Modes
Traffic Deaths are Down 31 Percent Since Vision Zero Launched in 2014
NEW YORK – The New York City Department of Transportation announced today that New York City ended
2025 with the fewest traffic deaths ever recorded, dating back to when record-keeping began in 1910. There were 205
recorded traffic deaths in 2025, a 19 percent decline from 253 fatalities last year, and one fewer than the previous
safest year on record in 2018, when 206 people were killed in traffic crashes. Overall, traffic deaths are down 31
percent since the launch of Vision Zero in 2014.The historic decline reflects continued progress under Vision Zero, including large-scale street safety redesigns;
additional space for pedestrians, cyclists, and buses; and expanded traffic enforcement initiatives, including
heightened crackdowns on ghost vehicles and dangerous driving behaviors over the past year.“No New Yorker should lose their life while walking, driving, or biking in our city,” said
Deputy Mayor of Operations Julia Kerson. “Vision Zero has shown that the choices we make—how
we design our streets and how we enforce traffic laws—save lives. Last year was the safest year on record, with the
fewest traffic deaths since records began in 1910. But one life lost is one too many. That’s why the Mamdani
administration will double down on street redesigns, protected bike lanes, and protected bus lanes that make our
streets safer and better for everyone.”NYC DOT cited the following highlights:
- Through December 31, 2025, the overall number of traffic fatalities is at 205, a 19 percent decline from the 253
fatalities recorded in 2024. - Outer boroughs experienced the sharpest declines in traffic deaths, with the Bronx and Queens seeing the
greatest safety improvements: - The Bronx experienced a 39 percent decline in traffic deaths, down from 54 fatalities in
2024 to 33 fatalities in 2025; - Queens experienced a 23 percent decline in traffic deaths, down from 74 in 2024 to 57 in
2025; - Manhattan experienced an 11 percent decline in traffic deaths, down from 44 in 2024 to 39
in 2025; - Brooklyn experienced a 9 percent decline in traffic deaths, down from 69 in 2024 to 63 in
2025; - And Staten Island remained roughly flat, from 12 fatalities in 2024 to 13 in 2025.
- Every major travel mode experienced a decline in traffic deaths in 2025, including among pedestrians, cyclists,
and motor vehicle occupants - Leading the decline was the sharp drop in deaths among drivers and occupants of motor vehicles by 40 percent,
and motorcycle users, by 32 percent. - Pedestrian fatalities remain at among the lowest levels ever and have also declined 9 percent, from 122
pedestrian deaths in 2024 to 111 in 2025. - In addition to fatalities, total traffic injuries and serious traffic injuries trended down in 2025. While
injury data is still being processed for the full year, as of December 15, total injuries are down 7.7 percent,
from 51,540 in 2024, to 47,557 in 2025. Serious injuries are down 2.8 percent from 3,031 in 2024 to 2,947 in
2025. - Child fatalities are near record lows, with 6 such fatalities recorded in 2025, down 63 percent from 16 recorded
2024.
NYC DOT has cited a variety of Vision Zero initiatives that have been among
the keys to the progress
in reducing fatalities in 2025. Those efforts include the dramatic expansion of protected bike lanes and newly
pedestrianized space—with more than 100 miles of protected bike lanes built and nearly 2 million square feet of
pedestrian space installed since the implementation of the city’s NYC Streets Plan. Protected bike lanes
have been shown to reduce deaths and serious
injuries for all road users by 18.1 percent.The agency also believes efforts to expand automated enforcement, alongside targeted police enforcement, have
helped spur substantial declines in fatalities of motor vehicle occupants and motorized two-wheeled devices,
particularly over the past four years following the COVID-19 pandemic. With this expanded enforcement,
fatalities involving the city’s most reckless drivers—including those who are not properly licensed,
involved in hit-and-runs, or had three or more prior convictions—dropped considerably. Those initiatives
include:Speed Cameras – Speed cameras have been shown to reduce deadly speeding by over 90 percent, and locations
where speed cameras had been recently installed saw 14 percent
fewer injuries and fatalities than control locations without cameras. In
2022, NYC DOT successfully advocated for the cameras to go to 24/7 operation, leading to a dramatic decline in deadly overnight and
weekend crashes.‘Ghost Car’ Crackdown – During the COVID-19 pandemic, the number of vehicles using unauthorized and fake
temporary tags expanded substantially, with crash statistics showing that such vehicles were far more likely to
be involved in deadly collisions. Through a regional law enforcement interagency task force, NYPD and sister
agencies have together seized
more than 100,000 illegal motorized vehicles and ghost cars since 2022.Aggressive NYPD enforcement on High Crash Priority Corridors – By focusing on the ground high visibility
enforcement on the highest-crash corridors, NYPD has been able to help achieve significant reductions in
injuries and fatalities.In the two boroughs with the highest percentage fatality declines, NYC DOT focused on major street improvement
projects in communities that had not received prior street redesigns – including new plazas as well as new
dedicated bus and bike lanes – treatments shown to reduce traffic crashes, making streets safer for all users:Bronx and Queens Bus Lanes – NYC DOT invested heavily in improving bus service in the Bronx and Queens
with numerous bus lane and pedestrian safety projects that have also been shown to significantly improve street
safety. Over the last three years, Bronx projects include University Avenue, Gun Hill Road, E. L. Grant Highway,
Pelham Parkway capital project, Westchester Avenue near Pelham Bay Park, and along the Washington Bridge to
Northern Manhattan. In Queens, the agency completed major bus lane projects over the years, including busways on
Main Street, Jamaica, and Archer avenues, Main Street, and bus lanes on 21st Street, Northern Boulevard, and
Queens Boulevard.Bronx and Queens Bicycle Network – With cycling surging citywide, NYC DOT has made unprecedented
investments to support cycling and micro-mobility around the city, including in the Bronx and Queens.In addition to the creation of e-scooter sharing service in the East Bronx, the agency has built a connected
network of bike lanes in areas of the Bronx lacking such infrastructure. This includes four miles of protected
bike lanes along major streets like Bronxdale Avenue, Hunts Point Avenue, Rosedale Avenue, and Soundview Avenue.
In 2025, NYC DOT began building out the Bronx
Harlem River Greenway, improving safety for everyone along
the riverfront.Queens has also seen major additions to its bicycle network as well as the first-ever expansion of e-scooter
service to Eastern Queens In 2023, DOT installed 2.5 miles of protected bike lanes on 11th Street, Jackson
Avenue, and 44th Drive in Long Island City. In 2024, the agency also completed the final phase of the Queens Boulevard redesign, adding protected bike
lanes in Sunnyside and Long Island
City, helping to reduce injuries and fatalities on what was formerly known as the ‘Boulevard of Death.’ NYC DOT
built on this success this year with the completion of the first phase of the 31st Avenue Bike
Boulevard, which added more than 26,000 square feet of new
pedestrian space to the street.###
Continue Reading
- Through December 31, 2025, the overall number of traffic fatalities is at 205, a 19 percent decline from the 253
-
Oil Futures Slip in First Trading Day of the Year – The Wall Street Journal
- Oil Futures Slip in First Trading Day of the Year The Wall Street Journal
- Oil prices settle lower after biggest annual loss since 2020 Reuters
- Oil prices flat ahead of OPEC+ meeting Investing.com
- Crude oil outlook remains mixed as geopolitical risks and excess inventories weigh on the market. 富途牛牛
- Oil Awaits a Catalyst as Brent Treads Water Crude Oil Prices Today | OilPrice.com
Continue Reading